Similar articles

• The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.

  Treseder SA, Rose S, Jenner P. Treseder SA, et al. Eur J Neurosci. 2001 Jan;13(1):162-70. doi: 10.1046/j.0953-816x.2000.01370.x. Eur J Neurosci. 2001. PMID: 11135014
• [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].

  Yoshimine N, Kuzuya F, Mori K, Sakamoto N. Yoshimine N, et al. Nihon Ronen Igakkai Zasshi. 1978 Nov;15(6):566-73. doi: 10.3143/geriatrics.15.566. Nihon Ronen Igakkai Zasshi. 1978. PMID: 732010 Japanese. No abstract available.
• Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.

  Jonkers N, Sarre S, Ebinger G, Michotte Y. Jonkers N, et al. J Neural Transm (Vienna). 2001;108(5):559-70. doi: 10.1007/s007020170056. J Neural Transm (Vienna). 2001. PMID: 11459076
• The pharmacology of Parkinson's disease: basic aspects and recent advances.

  Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE. Da Prada M, et al. Experientia. 1984 Nov 15;40(11):1165-72. doi: 10.1007/BF01946641. Experientia. 1984. PMID: 6437857 Review.
• Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

  Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Pinder RM, et al. Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001. Drugs. 1976. PMID: 782834 Review. No abstract available.